Design Therapeutics (DSGN) Competitors $6.35 +0.30 (+4.96%) Closing price 04:00 PM EasternExtended Trading$6.35 0.00 (0.00%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DSGN vs. NTLA, TLRY, EVO, SNDX, STOK, AMPH, RCUS, PHVS, TRML, and GPCRShould you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Intellia Therapeutics (NTLA), Tilray Brands (TLRY), Evotec (EVO), Syndax Pharmaceuticals (SNDX), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Arcus Biosciences (RCUS), Pharvaris (PHVS), Tourmaline Bio (TRML), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Design Therapeutics vs. Its Competitors Intellia Therapeutics Tilray Brands Evotec Syndax Pharmaceuticals Stoke Therapeutics Amphastar Pharmaceuticals Arcus Biosciences Pharvaris Tourmaline Bio Structure Therapeutics Intellia Therapeutics (NASDAQ:NTLA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Which has more volatility & risk, NTLA or DSGN? Intellia Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Which has better earnings and valuation, NTLA or DSGN? Design Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M32.01-$519.02M-$4.69-3.68Design TherapeuticsN/AN/A-$49.59M-$1.12-5.67 Does the media refer more to NTLA or DSGN? In the previous week, Intellia Therapeutics had 16 more articles in the media than Design Therapeutics. MarketBeat recorded 17 mentions for Intellia Therapeutics and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.87 beat Intellia Therapeutics' score of 0.62 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate NTLA or DSGN? Intellia Therapeutics presently has a consensus price target of $27.39, indicating a potential upside of 58.68%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 7 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.53Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in NTLA or DSGN? 88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is NTLA or DSGN more profitable? Design Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -908.48%. Design Therapeutics' return on equity of -27.15% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia Therapeutics-908.48% -57.48% -45.04% Design Therapeutics N/A -27.15%-26.07% SummaryIntellia Therapeutics beats Design Therapeutics on 8 of the 15 factors compared between the two stocks. Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DSGN vs. The Competition Export to ExcelMetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$344.54M$3.16B$5.80B$10.46BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-5.6721.03348.5626.86Price / SalesN/A447.99549.90125.65Price / CashN/A44.8326.0131.15Price / Book1.489.8315.536.50Net Income-$49.59M-$52.82M$3.29B$271.25M7 Day Performance8.36%3.47%200.87%3.69%1 Month Performance20.72%5.35%184.38%8.07%1 Year Performance7.99%13.26%325.51%29.65% Design Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DSGNDesign Therapeutics0.3125 of 5 stars$6.35+5.0%N/A+2.9%$344.54MN/A-5.6740Positive NewsNTLAIntellia Therapeutics4.4528 of 5 stars$12.35+6.7%$27.11+119.6%-28.7%$1.33B$52.86M-2.64600Analyst ForecastTLRYTilray Brands2.8088 of 5 stars$1.21+2.1%$1.94+60.8%-29.7%$1.33B$210.48M-0.522,842EVOEvotec1.7545 of 5 stars$3.68+5.1%$5.40+46.7%+7.4%$1.31B$777.33M0.004,827SNDXSyndax Pharmaceuticals3.8324 of 5 stars$15.03-5.1%$39.22+160.9%-19.1%$1.30B$23.68M-3.87110Analyst ForecastSTOKStoke Therapeutics3.7634 of 5 stars$23.33-0.3%$25.57+9.6%+66.5%$1.28B$199.89M27.38100Positive NewsAMPHAmphastar Pharmaceuticals4.0039 of 5 stars$27.15-0.4%$31.60+16.4%-43.8%$1.26B$731.97M10.182,028Positive NewsRCUSArcus Biosciences1.927 of 5 stars$11.73+1.3%$21.14+80.3%-24.8%$1.25B$262M-3.70500Positive NewsPHVSPharvaris2.4425 of 5 stars$23.62+1.0%$34.00+43.9%+30.0%$1.24BN/A-7.0430Gap UpTRMLTourmaline Bio0.8672 of 5 stars$47.70+0.1%$45.65-4.3%+107.3%$1.23BN/A-13.9144GPCRStructure Therapeutics2.9491 of 5 stars$21.27+5.3%$75.71+256.0%-43.8%$1.23BN/A-20.26136Gap Up Related Companies and Tools Related Companies NTLA Alternatives TLRY Alternatives EVO Alternatives SNDX Alternatives STOK Alternatives AMPH Alternatives RCUS Alternatives PHVS Alternatives TRML Alternatives GPCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DSGN) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DSGN Stock Alerts